Unraveling the Predictive Value of the Novel Global Immune-Nutrition-Inflammation Index (GINI) on Survival Outcomes in Patients with Grade 4 Adult-Type Diffuse Gliomas

Basit Öğe Kaydı
dc.authoridAydin, Asim Armagan/0000-0001-8749-9825
dc.contributor.authorAydin, Asim Armagan
dc.contributor.authorYuceer, Ramazan Oguz
dc.date.accessioned2024-10-26T18:06:04Z
dc.date.available2024-10-26T18:06:04Z
dc.date.issued2024
dc.departmentSivas Cumhuriyet Üniversitesi
dc.description.abstractBackground: This investigation evaluated the predictive and prognostic efficacy of the newly developed global immune-nutrition-inflammation index (GINI) in patients with grade 4 adult-type diffuse gliomas, comparing it with other established indices such as the systemic immune-inflammation index (SII), systemic inflammation response index (SIRI), and pan-immune-inflammation value (PIV). Method: A retrospective cohort included 198 patients diagnosed with isocitrate dehydrogenase (IDH)-mutant gr4 (grade 4) astrocytoma and IDH-wt (wilde-type) glioblastoma (GBM) gr4 treated with surgical resection, radiotherapy, and temozolomide. Patients were stratified into two groups based on their GINI values: low GINI (<5815) and high GINI (>= 5815). The primary endpoint was overall survival (OS). Results: High GINI was significantly associated with older age, poor performance status, multifocal tumors, and higher SII, SIRI, and PIV values (p < 0.005). The GINI demonstrated strong correlations with SII (r = 0.694), SIRI (r = 0.516), and PIV (r = 0.657) (p < 0.001). Patients with high GINI exhibited poorer OS (5.0 vs. 17.0 months) and PFS (5.0 vs. 13.0 months) in comparison to those with low GINI. Kaplan-Meier survival analysis revealed significantly prolonged OS and PFS among patients with low GINI (p < 0.001). Multivariate analysis identified high GINI as an independent negative risk factor for both PFS and OS. Conclusions: GINI is a robust predictor of clinical outcomes in IDH-mutant gr4 astrocytoma and IDH-wt GBM gr4, highlighting the crucial impact of nutrition and cancer cachexia. It shows superior prognostic value relative to the SII, SIRI, and PIV.
dc.identifier.doi10.3390/curroncol31090372
dc.identifier.endpage5039
dc.identifier.issn1198-0052
dc.identifier.issn1718-7729
dc.identifier.issue9
dc.identifier.pmid39330000
dc.identifier.scopus2-s2.0-85205056567
dc.identifier.scopusqualityQ2
dc.identifier.startpage5027
dc.identifier.urihttps://doi.org/10.3390/curroncol31090372
dc.identifier.urihttps://hdl.handle.net/20.500.12418/29348
dc.identifier.volume31
dc.identifier.wosWOS:001326543700001
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherMdpi
dc.relation.ispartofCurrent Oncology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectglioblastoma
dc.subjectglobal immune-nutrition-inflammation index
dc.subjectsurvival
dc.subjectcentral nervous system
dc.subjectbrain tumor
dc.subjectadult-type diffuse glioma
dc.subjectastrocytoma
dc.subjectbiomarker
dc.titleUnraveling the Predictive Value of the Novel Global Immune-Nutrition-Inflammation Index (GINI) on Survival Outcomes in Patients with Grade 4 Adult-Type Diffuse Gliomas
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksyonu
Scopus İndeksli Yayınlar Koleksiyonu